Armstrong, A.W., Ameen, A., Ferrucci, S. et al. (11 more authors) (2026) Real-world effectiveness and safety of 12 months of Tralokinumab in patients with atopic dermatitis. Dermatology and Therapy, 16. pp. 4993-5011. ISSN: 2193-8210
Abstract
Introduction
Atopic dermatitis (AD) is a chronic, inflammatory skin condition in which interleukin (IL)-13 is a key driver. Tralokinumab, an IL-13-targeting monoclonal antibody, has demonstrated efficacy and a favorable safety profile in patients with moderate-to-severe AD in phase 3 trials. However, data on long-term effectiveness and safety in routine clinical practice remain limited. This study aimed to assess changes in clinical signs and symptoms of AD and evaluate safety in patients treated with tralokinumab in a real-world setting.
Methods
TRACE is an international, non-interventional, prospective study of adults with AD prescribed tralokinumab and followed for up to 12 months of treatment. The primary outcome was investigator-assessed AD severity (Investigator’s Global Assessment [IGA], Eczema Activity and Severity Index [EASI], and/or SCORing AD [SCORAD]). Patient-reported outcomes (PROs) were collected if part of routine practice. Safety was also assessed.
Results
A total of 824 patients (mean age 44.1 years; 24.9% with prior biologic therapy) were included. At baseline, 414 (50.3%) patients had moderate AD (IGA 3), 281 (34.1%) had severe AD (IGA 4), mean EASI was 20.1, and mean SCORAD was 47.1. Early improvements in AD clinical signs and symptoms were sustained over 12 months of treatment with tralokinumab, with the percentage of composite responders (IGA 0/1, EASI-75, or SCORAD < 10) increasing from 5.3% at baseline to 79.1% at month 12. Rapid and sustained improvements in PROs were also reported throughout the study. AEs were reported by 232 (28.1%) patients, with the majority being non-serious and mild or moderate in severity. Conjunctivitis was reported in 4.4% of patients.
Conclusions
TRACE is the largest real-world study of tralokinumab to date. Treatment with tralokinumab over 12 months substantially improved signs and symptoms of AD as well as PROs across all outcome measures, providing evidence supporting the rapid and long-term effectiveness of tralokinumab. No new safety signals were identified.
Trial Registration
EU PAS register—EUPAS44659.
Metadata
| Item Type: | Article |
|---|---|
| Authors/Creators: |
|
| Copyright, Publisher and Additional Information: | © The Author(s) 2026. Open Access: This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| Keywords: | Atopic dermatitis; Real-world evidence; Tralokinumab |
| Dates: |
|
| Institution: | The University of Sheffield |
| Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health |
| Date Deposited: | 17 Sep 2026 11:09 |
| Last Modified: | 23 Oct 2026 11:45 |
| Status: | Published |
| Publisher: | Springer Science and Business Media LLC |
| Refereed: | Yes |
| Identification Number: | 10.1007/s13555-026-01869-w |
| Related URLs: | |
| Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:245580 |
Download
Filename: s13555-026-01869-w.pdf
Licence: CC-BY-NC 4.0

CORE (COnnecting REpositories)
CORE (COnnecting REpositories)